Itraconazole for severe asthma with fungal sensitivity

Abstract

Background: Severe asthma with fungal sensitivity (SAFS) is a recently described form of asthma that is difficult to treat with conventional inhaled corticosteroids. Antifungal therapies such as itraconazole might be an option. Objective: To discuss the data from a study evaluating efficacy and safety of itraconazole therapy in SAFS. Methods/results: Itraconazole therapy was found to improve quality of life and reduce immune response, with no impact on lung function. Conclusions: Itraconazole may be a promising therapy in SAFS, provided its potential of reducing airway inflammation is further documented.

Keywords::

• allergic bronchopulmonary aspergillosis
• fungal sensitisation
• itraconazole
• severe asthma